At least four isoforms of PALB2 are known to exist, this antibody will detect all four isoforms.
Purification
PALB2 Antibody is affinity chromatography purified via peptide column.
Immunogène
PALB2 antibody was raised against a 15 amino acid synthetic peptide from near the carboxy terminus of human PALB2. The immunogen is located within amino acids 940 - 990 of PALB2.
PALB2
Reactivité: Humain
IHC
Hôte: Lapin
Polyclonal
unconjugated
Indications d'application
PALB2 antibody can be used for detection of PALB2 by Western blot at 1 - 2 μ,g/mL.
Antibody validated: Western Blot in human samples. All other applications and species not yet tested.
Restrictions
For Research Use only
Format
Liquid
Concentration
1 mg/mL
Buffer
PALB2 Antibody is supplied in PBS containing 0.02 % sodium azide.
Agent conservateur
Sodium azide
Précaution d'utilisation
This product contains Sodium azide: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.
Stock
-20 °C,4 °C
Stockage commentaire
PALB2 antibody can be stored at 4°C for three months and -20°C, stable for up to one year. As with all antibodies care should be taken to avoid repeated freeze thaw cycles. Antibodies should not be exposed to prolonged high temperatures.
anticorps PALB2, anticorps Fancn, anticorps si:ch211-14k19.9, anticorps FANCN, anticorps PNCA3, anticorps 4732427B05, anticorps BC066140, anticorps RGD1304759, anticorps partner and localizer of BRCA2, anticorps partner and localizer of BRCA2 L homeolog, anticorps PALB2, anticorps palb2, anticorps palb2.L, anticorps Palb2
Sujet
PALB2 Antibody: The breast cancer early onset proteins BRCA1 and BRCA2 are central to the repair of DNA damage by homologous recombination and are strongly associated with inherited breast and ovarian cancer. The protein PALB2 is required for the localization of BRCA2 to sites of DNA damage and like BRCA1 and 2 is a breast cancer susceptibility gene. PALB2 is thought to function through directly binding to BRCA1, which allows the PALB2 protein to organize BRCA2 and the recombinase RAD51 at the site of DNA damage. Analysis of the BRCA1-PALB2-BRCA2-RAD51network may allow predictions to be made of the responsiveness of a particular tumor to therapeutic treatments.